Enzon Pharmaceuticals Inc (NASDAQ:ENZN)

1.06
Delayed Data
As of Mar 31
 0.00 / 0.00%
Today’s Change
0.73
Today|||52-Week Range
1.66
+7.17%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$46.8M

Company Description

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company. The company engages in the research and development of innovative therapeutics for cancer patients with high unmet medical needs. Its drug-development programs utilize two platforms such as customized PEGylation linker technology and third-generation mRNA-targeting agents utilizing the locked nucleic acid technology. The company receives royalties on marketed products that utilize PEGylation platform, including PegIntron, Sylatron, Macugen, CIMZIA, OMONTYS, Oncaspar and Adagen. Enzon Pharmaceuticals was founded by Abraham Abuchowski on September 17, 1981 and is headquartered in Piscataway, NJ.

Contact Information

Enzon Pharmaceuticals, Inc.
20 Kingsbridge Road
Piscataway New Jersey 08854
P:(732) 980-4500
Investor Relations:

Employees

Shareholders

Mutual fund holders8.06%
Other institutional43.73%
Individual stakeholders23.20%

Top Executives

George W. HebardChief Executive Officer, COO & Secretary
Richard L. FeinsteinChief Financial Officer & Vice President-Finance

To view my watchlist

Not a member yet?

Sign up now for a free account